© The Financial Times Ltd 2014 FT and 'Financial Times' are trademarks of The Financial Times Ltd.
As of Oct 21, 2014, the consensus forecast amongst 66 polled investment analysts covering AstraZeneca plc advises investors to hold their position in the company. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Jul 31, 2009. The previous consensus forecast advised that AstraZeneca plc would outperform the market.
|Last year||3 months ago||2 months ago||4 weeks ago||Latest|
Share price forecast information is not available for
|Div growth (TTM)||0.00%|
On Jul 31, 2014,
The next earnings announcement is expected on Nov 06, 2014. View Full Interim Financials
|Average growth rate||+2.18%|
The next earnings announcement from
|Average growth rate||-4.07%|
AstraZeneca PLC had 2nd quarter 2014 revenues of 6.45bn. This bettered the 6.29bn consensus of the 13 analysts covering the company. This was 0.59% above the prior year's 2nd quarter results. View Full Interim Financials
|Average growth rate||+1.03%|
AstraZeneca PLC had revenues for the full year 2013 of 25.71bn. This was 8.09% below the prior year's results. View Full Annual Financials
|Average growth rate||-5.61%|